20 15, 1 approved for global marketing and widely used in clinical treatment.
Chidamide is the first oral inhibitor of subtype-selective histone deacetylase approved for marketing in the world, and the first original new drug authorized by developed countries such as the United States in China.
Drug characteristics
The first indication of dabenamine is recurrent and refractory peripheral T-cell lymphoma. Early clinical results show that the clinical benefit rate of patients is nearly 50%, and the survival time is obviously prolonged.
Chidamine is an original new drug in China, the first subtype-selective histone deacetylase inhibitor in the world, and the first original new drug in China authorized by developed countries such as the United States. The first indication is recurrent and refractory peripheral T-cell lymphoma.
It is precisely because of subtype selectivity that chidamide has a very unique anti-tumor mechanism, such as activating the immune function of patients with anti-tumor cells.
Significance of research and development
It means that China has its own original anti-cancer drugs, and China's drug research and development has gradually entered the stage of independent innovation at the same level or even ahead of developed countries from imitation and high imitation.
This move will fill the gap in the treatment of T-cell lymphoma in China, and also mark the significant improvement of the core technology and ability of the whole process integration of structure-based molecular design, target research, safety evaluation, clinical development and industrialization in China. It is a historic breakthrough in China's pharmaceutical industry.